Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 3003891A

Next Previous
X
Search
Drug Profile

GSK 3003891A

Alternative Names: GSK-3003891A; GSK-3003892A; GSK-3003893A; GSK-3003895A; GSK-3003896A; GSK-3003898A; GSK-3003899A; Pre F protein - GSK; RSV vaccine - GSK; RSV-PreF vaccine - GSK

Latest Information Update: 28 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class Respiratory syncytial virus vaccines; Viral fusion proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 28 Sep 2023 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(Prevention) in Canada (IM, Injection)
  • 05 Feb 2018 GlaxoSmithKline completes the phase II RSV F-021 trial in Respiratory syncytial virus infections (Prevention) in Belgium, Estonia, France and Germany (IM) (NCT02956837)
  • 14 Aug 2017 GlaxoSmithKline withdraws prior to enrolment a phase II trial in Respiratory syncytial virus infections (In infants, Prevention, In volunteers) in USA, Finland, Spain and United Kingdom (IM) (NCT03191383) (EudraCT2016-002733-30)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top